ZennCell Introduces Independently Developed Functional Ingredients at 'Vitafoods Europe'

Genensel announced on the 17th that it participated in the ‘VitaFoods Europe 2024’ exhibition held in Geneva, Switzerland, from the 14th to the 16th, conducting marketing activities for its independently developed functional ingredients.

Celebrating its 27th edition this year, ‘VitaFoods Europe’ is the world's largest exhibition in the field of health functional foods and pharmaceutical ingredients. Approximately 1,100 companies and 20,000 attendees from over 160 countries worldwide participated.

Genensel, together with its sales partner FMCG Korea, set up a booth within the Korea Pavilion and introduced the excellent clinical results and characteristics of its developed ingredients, gaining positive responses from participants. They showcased ‘CA-HE50’, a dual-function individual recognition ingredient approved by the Ministry of Food and Drug Safety for improving eye health due to aging and liver damage, the premenstrual syndrome relief material ‘Premensia’, and follow-up pipeline candidates including materials for joint health, body fat improvement, and cognitive function enhancement.

‘CA-HE50’, which is about to be commercialized domestically, also attracted significant interest from overseas companies in Asia, Europe, and North America.

A Genensel representative stated, "Not only do the developed materials possess market competitiveness, but we have also recently secured large-scale clean raw material complexes and production facilities. We will develop them into differentiated global materials through locally tailored strategies."

Genensel plans to participate in multiple overseas health functional food and pharmaceutical ingredient exhibitions this year, including CPHI China (China), VitaFoods Asia (Thailand), HI Japan (Japan), and Supply Side WEST (USA).

This content was produced with the assistance of AI translation services.